NCT05076279Active, not recruiting
Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01)
Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01) Phase II Clinical Trial
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
The aim of this study is to verify the safety and efficacy of single or reduced ports laparoscopic gastrectomy for advanced gastric cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 108 (actual)
- First submitted
- 29 Sept 2021
- Start date
- 15 Nov 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Seoul National University Bundang Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05076279
What you commit to
- Study type: Interventional
- Participants enrolled: 108
- From 15 Nov 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who have previously had gastrectomy.
- Patients who are taking antithrombotic drugs, including antiplatelet drugs and anticoagulants, and cannot safely stop before surgery
Other
- Those who have a laparotomy except for appendectomy, cholecystectomy or cesarean section.
- Patients with clinical (preoperative or intraoperative) stage T4b accompanied by infiltration of surrounding organs
- Those with bulky lymph nodes (single nodules over 3 cm or multiple nodules over 1.5 cm)
- Patients with confirmed distant metastasis (M1)
- Severe liver cirrhosis
- Patients who is judged by the investigator to be inappropriate for this study
Who the study is looking for
- Patients who have confirmed that participants have advanced gastric cancer at clinical stage T2 or higher and who can undergo distal gastrectomy for primary gastric cancer who have consented to single-port and reduced-port laparoscopic gastric cancer surgery
- Patients diagnosed with locally advanced gastric cancer in which no enlarged lymph nodes were observed in the preoperative examination, or lymph node metastases confined to the left gastric artery or perigastric area were suspected.
- Those who have not been treated for systemic inflammatory disease before surgery
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.